Clinical trial
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
NCT05516758 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 31, 2022
- Completion date
- January 17, 2025
- Enrollment
- 491 (actual)
- Sites
- 131
Conditions
As the registry lists them; a condition with its own page is linked.
arthritis, autoimmune diseases, connective tissue diseases, immune system diseases, joint diseases, musculoskeletal diseases, rheumatic diseases, rheumatoid arthritis